# US 2026/0092072 A1 · Inhibitors of aldose reductase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092072 A1
- Document ID: US20260092072A1
- Status: Published application
- Kind: A1
- Application number: 19/414,626
- Filed: 2025-12-10
- Published: 2026-04-02
- Earliest claimed: 2019-04-01
- Assignees: Applied Therapeutics, Inc.
- Applicants: Applied Therapeutics, Inc.
- Inventors: Andrew WASMUTH
- Web page: https://patentgrep.com/patent/US20260092072A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 487/04: Ortho-condensed systems
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

## Claims

### Claim at position 1

1-4. (canceled)

### Claim 5

A compound of Formula (II)
wherein,
X1 is N or CR1;
X2 is N, CR2, or S;
X3 is N, CR3, or a bond;
X4 is N or CR4; with the proviso that when X2 is S, X1 is CR1, X4 is CR4, and X3 is a single bond; or that two or three of X1, X2, X3, or X4 are N;
Y is a bond, C═O, C═S, C═NH, or C═N(C1-C4)-alkyl;
Z is
A1 is NR9, O, S or CH2;
A2 is N or CH;
A3 is NR9, O, or S;
R1 through R8 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl, or (C1-C4)-alkylsulfonyl; or two of R1 through R4 or two of R5 through R8 taken together are (C1-C4)-alkylenedioxy;
R9 is hydrogen, (C1-C4)-alkyl, or C(O)O—(C1-C4)-alkyl;
X6 is S(O)2—OR13, S(O)2—NHR13, heteroaryl, or heterocycloalkyl; and
R13 is H or (C1-C6)-alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R5, R7 and R8 are each H; and R6 is halogen of haloalkyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R6 is trifluoromethyl.

### Claim at position 5

8-10. (canceled)

### Claim 11 (depends on 5)

A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

### Claim at position 7

12-28. (canceled)